Bradford C. Webb, PhD
Venture Partner @ Claremont Creek Ventures
San Francisco Bay Area, United States
Bradford C. Webb, PhD is a Series B investor at Claremont Creek Ventures in San Francisco Bay Area focused on Biotechnology and Health Care. Brad Webb is an experienced entrepreneur and investor in the biomedical and biotech industries. In addition to his active role as a Venture Partner at Claremont Creek, Brad consults with other venture firms specializing in medical and pharmaceutical early-stage investing.After receiving a PhD in Biochemistry and Molecular Biology from theUniversity of California at Santa Barbara in 1979, Brad joined 3M Company's ophthalmology products division as a research and development scientist working on designs for post-cataract surgery intraocular lenses. He also supervised human clinical trials and FDA approval processes for 3M. After leaving 3M, Brad led or participated in several start-up ventures in the ophthalmic products industry, with responsibility for research, clinical trials and FDA affairs.In 1988 Brad founded Vision Biology, Inc., to develop new viscoelastic products for use in eye surgery. Vision Biology's revolutionary patented Viscoelastic Surgical Fluid for use during cataract surgery was licensed to Alcon Laboratories in 1996. Brad spent several years consulting for Alcon on a variety of medical product research and development projects, and recently has participated in investments in biotech and medical technology companies.Brad is a member of Tech Coast Angels, a Southern California based Angel group, is active with UC Santa Barbara technology programs, and will be instrumental in extending the reach of Claremont Creek into the broader Southern California technology region.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Bradford C. Webb, PhD invests in
Stages Bradford C. Webb, PhD invests in
Countries Bradford C. Webb, PhD invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (38%)
- Health Care 2 (25%)
- Medical 1 (13%)
- Genetics 1 (13%)
- Hospital 1 (13%)
Stage
- Series B 2 (25%)
- Series C 2 (25%)
- Series A 1 (13%)
- Series D 1 (13%)
- Debt Financing 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies andantigens or hybridization of nucleic acids. | $44M / Series C / Aug 18, 2015 | ||
| NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii. It utilizes hundreds of millions of raw human, biological,pharmacological, and clinical data points.The company was founded in 2008 and headquartered in San Mateo, California. | $2M / Series A / Aug 17, 2015 | ||
| Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $37.4M / Series D / Dec 23, 2014 | ||
| Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $25M / Debt Financing / May 21, 2014 | ||
| NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii. It utilizes hundreds of millions of raw human, biological,pharmacological, and clinical data points.The company was founded in 2008 and headquartered in San Mateo, California. | $3.5M / Series A / Jun 26, 2013 | ||
| Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $12.5M / Series C / May 30, 2012 | ||
| Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies andantigens or hybridization of nucleic acids. | $11.8M / Series B / Mar 30, 2012 | ||
| Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $11M / Series B / Mar 25, 2011 |
Co-Investors
About Claremont Creek Ventures
Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in companies that serve essential, broad-impact industries with innovative digital solutions that increase efficiency or create entirely new high-growth, high-margin businesses. As part of CCV’s investment strategy, the firm practices “life cycle venturing”: establishing in-depth, active relationships with entrepreneurs alongside or even ahead of early-stage funding events. Claremont Creek Ventures has invested in over 40 companies including Clean Power Finance, EcoATM, and Natera and manages more than $300 million across two funds. Visit www.claremontcreek.com.
Claremont Creek Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gianna Conci Orozco
Finance Manager
|
|||
|
Harveen Sethi
Associate
|
|||
Nathaniel Goldhaber
Co-Founder & Managing Director
|
|||
|
Bradford C. Webb, PhD
Venture Partner
|
|||
Nathaniel Goldhaber
Co-Founder & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bradford C. Webb, PhD invest in?
Bradford C. Webb, PhD invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bradford C. Webb, PhD?
Public channels for Bradford C. Webb, PhD include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bradford C. Webb, PhD last invest?
The most recent investment recorded for Bradford C. Webb, PhD closed in Aug 2015. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
